Regeneron announces new, updated data from hematology pipeline at ASH meeting

Regeneron Pharmaceuticals announced that new and updated data from its hematology pipeline will be shared in 19 abstracts at the American Society of Hematology, ASH, Annual Meeting from December 9 to 12 in San Diego, CA. These include research across six investigational medicines that span eight difficult-to-treat blood cancers and disorders. Together, these presentations showcase the diversity of approaches Regeneron is advancing through its hematology pipeline and its dedication to leading-edge research. At ASH, 10 abstracts will feature updated data and analyses for Regeneron’s most advanced investigational blood cancer medicine, odronextamab, in relapsed/refractory follicular lymphoma and R/R diffuse large B-cell lymphoma. Among them are three oral presentations from its pivotal trial, including: the final analysis in R/R DLBCL patients; a comprehensive analysis of minimal residual disease status and circulating tumor DNA profiling in R/R FL and DLBCL patients; and updated analyses and long-term follow-up of efficacy, safety and patient reported outcomes in R/R FL. Furthermore, the company will share long-term survival outcomes and a responder analysis for odronextamab from a Phase 1 trial in R/R DLBCL patients who have progressed after CAR-T therapy, a patient population who have a particularly dismal prognosis and limited effective treatment options.